EPS Bio Technology Bilan de santé

Santé financière contrôle des critères 6/6

EPS Bio Technology possède un total de capitaux propres de NT$313.2M et une dette totale de NT$13.6M, ce qui porte son ratio d'endettement à 4.4%. Son actif total et son passif total sont NT$565.1M et de NT$251.9M. L'EBIT de EPS Bio Technology est NT$33.7M ce qui fait que son ratio de couverture des intérêts -44. Elle dispose de liquidités et de placements à court terme de NT$151.3M.

Informations clés

4.4%

Ratio d'endettement

NT$13.63m

Dette

Ratio de couverture des intérêts	-44x
Argent liquide	NT$151.32m
Fonds propres	NT$313.21m
Total du passif	NT$251.87m
Total des actifs	NT$565.09m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Apr 16

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

Mar 20

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Feb 22

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Feb 01

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Jan 04

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

Dec 14

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4183 ( NT$389.4M ) dépassent ses passifs à court terme ( NT$142.2M ).

Passif à long terme: Les actifs à court terme de 4183 ( NT$389.4M ) dépassent ses passifs à long terme ( NT$109.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4183 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4183 a été réduit de 9% à 4.4% au cours des 5 dernières années.

Couverture de la dette: La dette de 4183 est bien couverte par le flux de trésorerie opérationnel ( 72.7% ).

Couverture des intérêts: 4183 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

EPS Bio Technology Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.43 in 3Q 2023)

EPS Bio Technology Corp. to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: EPS: NT$0.34 (vs NT$0.18 in 2Q 2023)

Now 21% overvalued after recent price rise

EPS Bio Technology Corp. to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$0.80 per share

Dividend reduced to NT$0.80

First quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.10 in 1Q 2023)

EPS Bio Technology Corp. Approves Dividend for the Year 2023

Investor sentiment improves as stock rises 21%

Full year 2023 earnings released: EPS: NT$0.88 (vs NT$1.07 in FY 2022)

EPS Bio Technology Corp., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.21 in 2Q 2022)

EPS Bio Technology Corp. Appoints Lin, Chih-Heng as Research and Development Officer

New major risk - Dividend sustainability

Upcoming dividend of NT$0.98 per share at 4.7% yield

EPS Bio Technology Corp. Approves Dividend Proposal of 2022

Full year 2022 earnings released

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: NT$0.21 (vs NT$0.27 in 2Q 2021)

EPS Bio Technology Corp. Announces Appointment of Members of Compensation Committee

Upcoming dividend of NT$0.70 per share

Eps Bio Technology Corp. Approves Cash Dividend for the Year 2021, Payable on August 4, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.49 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.59 in 2Q 2020)

Upcoming dividend of NT$1.20 per share

First quarter 2021 earnings released: NT$0.22 loss per share (vs NT$0.18 profit in 1Q 2020)

Board of Directors Approves Proposal to Distribute Dividends

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

EPS Bio Technology Corp., Annual General Meeting, Jun 28, 2021

Full year 2020 earnings released: EPS NT$1.33 (vs NT$0.78 in FY 2019)

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.49

New 90-day low: NT$20.00

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines